| NTRK fusion-positive cancers and TRK inhibitor therapy E Cocco, M Scaltriti, A Drilon Nature reviews Clinical oncology 15 (12), 731-747, 2018 | 1358 | 2018 |
| Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma S Zhao, M Choi, JD Overton, S Bellone, DM Roque, E Cocco, F Guzzo, ... Proceedings of the National Academy of Sciences 110 (8), 2916-2921, 2013 | 338 | 2013 |
| HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ... Cancer discovery 10 (5), 674-687, 2020 | 236 | 2020 |
| Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial–mesenchymal transition S Zhao, S Bellone, S Lopez, D Thakral, C Schwab, DP English, J Black, ... Proceedings of the National Academy of Sciences 113 (43), 12238-12243, 2016 | 224 | 2016 |
| Resistance to TRK inhibition mediated by convergent MAPK pathway activation E Cocco, AM Schram, A Kulick, S Misale, HH Won, R Yaeger, P Razavi, ... Nature medicine 25 (9), 1422-1427, 2019 | 201 | 2019 |
| ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer G Xu, S Chhangawala, E Cocco, P Razavi, Y Cai, JE Otto, L Ferrando, ... Nature genetics 52 (2), 198-207, 2020 | 184 | 2020 |
| Serum amyloid A: a novel biomarker for endometrial cancer E Cocco, S Bellone, K El‐Sahwi, M Cargnelutti, N Buza, FA Tavassoli, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 181 | 2010 |
| Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF/KRAS are enriched for targetable kinase fusions E Cocco, J Benhamida, S Middha, A Zehir, K Mullaney, J Shia, R Yaeger, ... Cancer research 79 (6), 1047-1053, 2019 | 158 | 2019 |
| TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations EY Rosen, DA Goldman, JF Hechtman, R Benayed, AM Schram, E Cocco, ... Clinical Cancer Research 26 (7), 1624-1632, 2020 | 148 | 2020 |
| Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell … S Bellone, ER Siegel, E Cocco, M Cargnelutti, DA Silasi, M Azodi, ... International journal of gynecological cancer 19 (5), 860-866, 2009 | 121 | 2009 |
| In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma K El-Sahwi, S Bellone, E Cocco, M Cargnelutti, F Casagrande, M Bellone, ... British journal of cancer 102 (1), 134-143, 2010 | 120 | 2010 |
| FOXA1 mutations reveal distinct chromatin profiles and influence therapeutic response in breast cancer A Arruabarrena-Aristorena, JLV Maag, S Kittane, Y Cai, WR Karthaus, ... Cancer cell 38 (4), 534-550. e9, 2020 | 100 | 2020 |
| Improved ip drug delivery with bioadhesive nanoparticles Y Deng, F Yang, E Cocco, E Song, J Zhang, J Cui, M Mohideen, ... Proceedings of the National Academy of Sciences 113 (41), 11453-11458, 2016 | 97 | 2016 |
| Eradication of chemotherapy‐resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of clostridium perfringens enterotoxin F Casagrande, E Cocco, S Bellone, CE Richter, M Bellone, P Todeschini, ... Cancer 117 (24), 5519-5528, 2011 | 91 | 2011 |
| Polymerase ε (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients S Bellone, F Centritto, J Black, C Schwab, D English, E Cocco, S Lopez, ... Gynecologic oncology 138 (1), 11-17, 2015 | 90 | 2015 |
| The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers EY Rosen, HH Won, Y Zheng, E Cocco, D Selcuklu, Y Gong, ... Nature communications 13 (1), 1450, 2022 | 80 | 2022 |
| Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2) E Cocco, F Javier Carmona, P Razavi, HH Won, Y Cai, V Rossi, C Chan, ... Science signaling 11 (551), eaat9773, 2018 | 79 | 2018 |
| Prevalence and role of HER2 mutations in cancer E Cocco, S Lopez, AD Santin, M Scaltriti Pharmacology & therapeutics 199, 188-196, 2019 | 78 | 2019 |
| Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro S Bellone, E Bignotti, S Lonardi, F Ferrari, F Centritto, A Masserdotti, ... Gynecologic oncology 144 (1), 146-152, 2017 | 74 | 2017 |
| Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy L Zammataro, S Lopez, S Bellone, F Pettinella, E Bonazzoli, E Perrone, ... Proceedings of the National Academy of Sciences 116 (45), 22730-22736, 2019 | 72 | 2019 |
Ileana Bortolomaitiget- ospedale san raffaele-IRSایمیل تأیید شده در hsr.it